期刊
SEMINARS IN THROMBOSIS AND HEMOSTASIS
卷 34, 期 3, 页码 256-266出版社
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0028-1082269
关键词
antiphospholipid (aPL) antibodies; antiphospholipid syndromes; APS; treatment
This article provides a review of the various types of antiphospholipid (aPL) antibodies and antiphospholipid syndromes, their prevalence, presumed origin, relationship to autoimmunity in general, and their role in the body's defenses and apoptosis. New hypotheses such as the role of antibodies to beta 2 glycoprotein I (beta 2GPI) and the signaling of toll-like receptors are also discussed, as is the spectrum of clinical manifestations associated with the demonstration of these antibodies, now assumed to be pathogenic. A distinction is made between antibodies present in sera of patients with a variety of microanglopathic syndromes (MAPS; e.g., HELLP syndrome, thrombotic thrombocytopenic purpura, and thrombotic microanglopathic syndromes). In these conditions, the antibodies might not be pathogenic but, alternatively, generated by small vessel endothelial damage. These conditions are differentially referred to as microanglopathic antiphospholipid-associated syndromes, and they should be differentiated from the microvascular occlusions that are seen in the antiphospholipid syndrome. Current treatments of the antiphospholipid syndrome are briefly reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据